An anti-aging drug may help protect the brain before Alzheimer's symptoms begin
A study suggests that a drug used to prevent organ rejection may improve brain blood flow in people with a genetic risk for Alzheimer's. Researchers found that low-dose rapamycin improved blood flow in middle-aged adults with the APOE4 gene variant, which is linked to higher Alzheimer's risk. The results raise hopes for early intervention before symptoms appear. The study was led by researchers at the University of Missouri-Columbia and focused on preventing brain aging before memory loss begins.
A drug used to prevent organ rejection improved brain blood flow in people with a genetic risk for Alzheimer's. The study involved middle-aged adults with the APOE4 gene variant and showed that low-dose rapamycin had positive effects on brain circulation.
Improving brain blood flow early could help prevent or delay Alzheimer's in people at risk. This approach offers a potential way to address the disease before symptoms appear, which could lead to better outcomes for those with a genetic predisposition.
The study shows how existing medications can be repurposed to address health risks early, offering a hopeful and practical path toward preventing serious diseases. It highlights the importance of early intervention and the potential for medical breakthroughs to improve quality of life.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.